Translational PBPK/PD modelling
Earlier work on PBPK/PD models, drug disposition, and cross-species extrapolation.
Before my PhD, I worked on translational PBPK/PD and drug-disposition questions at China Pharmaceutical University.
This included a PBPK-PD model for topoisomerase inhibitor antibody-drug conjugates, cross-species PBPK modelling for SPT-07A, and studies of transporter-mediated drug disposition in liver-injury models. Across these projects, the common thread was mechanistic interpretation: using models to connect experimental data, tissue exposure, pharmacological effect, and toxicity risk.
That background now informs my clinical pharmacology work, especially the habit of making assumptions explicit and asking whether a model result can support a real decision.